Increasing proportion of vancomycin-resistance among enterococcal bacteraemias in Switzerland: a 6-year nation-wide surveillance, 2013 to 2018. by Piezzi, Vanja et al.
1www.eurosurveillance.org
Surveillance
Increasing proportion of vancomycin resistance among 
enterococcal bacteraemias in Switzerland: a 6-year 
nation-wide surveillance, 2013 to 2018
Vanja Piezzi1 , Michael Gasser2 , Andrew Atkinson1 , Andreas Kronenberg2 , Danielle Vuichard-Gysin3 , Stephan Harbarth4 , Jonas 
Marschall1 , Niccolò Buetti1,4,5, on behalf of the Swiss Centre for Antibiotic Resistance (ANRESIS)6 , on behalf of the National 
Centre for Infection Control (Swissnoso)7
1. Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland
2. Institute for Infectious Diseases, University of Bern, Bern, Switzerland
3. Department of Internal Medicine, Cantonal Hospital Muensterlingen, Thurgau Hospital Group, Kreuzlingen, Switzerland
4. Infection Control Programme, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland
5. IAME, DeSCID team, INSERM, Université Paris Diderot and Sorbonne Paris Cité, Paris, France
6. The members of the advisory board of ANRESIS are acknowledged at the end of the article
7. The members of Swissnoso are acknowledged at the end of the article
Correspondence: Niccolò Buetti (niccolo.buetti@gmail.com)
Citation style for this article: 
Piezzi Vanja , Gasser Michael , Atkinson Andrew , Kronenberg Andreas , Vuichard-Gysin Danielle , Harbarth Stephan , Marschall Jonas , Buetti Niccolò , on behalf 
of the Swiss Centre for Antibiotic Resistance (ANRESIS) , on behalf of the National Centre for Infection Control (Swissnoso) . Increasing proportion of vancomycin-
resistance among enterococcal bacteraemias in Switzerland: a 6-year nation-wide surveillance, 2013 to 2018. Euro Surveill. 2020;25(35):pii=1900575. https://doi.
org/10.2807/1560-7917.ES.2020.25.35.1900575 
Article submitted on 16 Feb 2020 / accepted on 16 Feb 2020 / published on 03 Sep 2020
Background: Vancomycin-resistant enterococci (VRE), 
mostly  Enterococcus faecium, are multidrug-resistant 
microorganisms that can cause nosocomial infec-
tions. VRE has increased throughout many European 
countries, but data from Switzerland are scarce. Aim: 
The aim of this work was to characterise the epide-
miology of enterococcal bacteraemias in Switzerland 
with a focus on VRE. Methods: In this observational 
study, we retrospectively investigated bacteraemias 
from 81 healthcare institutions from January 2013 
to December 2018 using data from the Swiss Centre 
for Antibiotic Resistance. Only the first blood isolate 
with E. faecalis or E. faecium from an individual patient 
was considered. We analysed the annual incidences 
of enterococcal bacteraemias and determined the 
proportion of VRE over time. We also assessed epi-
demiological factors potentially associated with VRE 
bacteraemia. Results: We identified 5,369 enterococ-
cal bacteraemias, of which 3,196 (59.5%) were due 
to E. faecalis and 2,173 (40.5%) to E. faecium. The inci-
dence of enterococcal bacteraemias increased by 3.2% 
per year (95% confidential interval (CI): 1.6–4.8%), 
predominantly due to a substantial increase in E. fae-
calis  bacteraemic episodes. Vancomycin resistance 
affected 30 (1.4%) E. faecium and one E. faecalis bac-
teraemic episodes. Among all  E. faecium  bacterae-
mias, the proportion of vancomycin-resistant isolates 
increased steadily from 2013 to 2018 (2% per year; 
95% CI: 1.5–2.9%). No independent epidemiological 
factor for higher prevalence of vancomycin-resistant E. 
faecium  bacteraemias was identified. Conclusions: 
Vancomycin-resistant E. faecium bacteraemias remain 
infrequent in Switzerland. However, an important 
increase was observed between 2013 and 2018, high-
lighting the need for implementing active surveillance 
and targeted prevention strategies in the country.
Introduction
Enterococcus faecalis  and  E. faecium  are the most 
common enterococci in the human gastrointestinal 
flora and the two most common species responsible 
for invasive enterococcal infections [1]. In Europe,  E. 
faecalis  and  E. faecium  are the fourth and fifth most 
frequent causative pathogen of bloodstream infections 
and a significant increase in enterococcal bacterae-
mias, particularly E. faecium, has been observed from 
2002 to 2008 [2]. A similar trend was reported up to 
2014 in a Swiss surveillance study [3].
In the last decades, vancomycin-resistant entero-
cocci (VRE), mostly  E. faecium, emerged worldwide 
as nosocomial multidrug-resistant microorganisms 
[4-6]. The morbidity and mortality associated with 
VRE bacteraemia are increased compared with infec-
tions due to susceptible enterococci, despite the use 
of effective antibiotics [7]. In Europe (countries in 
the European Union and in the European Economic 
Areas), according to the 2018 surveillance report of 
the European Antimicrobial Resistance Network (EARS-
Net), the national percentages for vancomycin resist-
ance among  E. faecium  isolates ranged from 0.0% to 
59.1%. Several countries with already high resistance 
rates reported further increases during 2014–2018 [8]. 
Switzerland is not part of the EARS-Net and national 
vancomycin-resistant  E. faecium  data have not been 
published for infection control purposes to date. so
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However, since 2009 several small VRE outbreaks have 
been documented in the country [9-13]. At the begin-
ning of 2018, a large monoclonal outbreak with van-
comycin-resistant  E. faecium  sequence type (ST) 796 
affected several hospitals in the north-eastern part of 
Switzerland [14].
We hypothesised that the national epidemiological 
situation of enterococcal bacteraemias is evolving 
quickly and that invasive vancomycin-resistant  E. fae-
cium  infections are increasing. We therefore wanted 
to describe patterns and trends of enterococcal bacte-
raemias in Switzerland from 2013 to 2018 with a focus 
on vancomycin-resistant isolates, using data from the 
Swiss Centre for Antibiotic Resistance (ANRESIS).
Methods
Study design and setting
We performed a retrospective observational analysis of 
enterococcal bacteraemias in Switzerland over 6 years, 
from 1 January 2013 to 31 December 2018. We used 
prospectively collected epidemiological and microbio-
logical data from a nationwide microbiology laboratory 
surveillance system.
Data source
The isolates were identified by a search in the ANRESIS 
database for all blood cultures positive for  E. faeca-
lis or E. faecium. ANRESIS collects all routine antibiotic 
resistance data from currently 24 clinical microbiol-
ogy laboratories homogeneously distributed across 
Switzerland. Each participating laboratory gathers 
data from several hospitals and submits results on a 
voluntary basis (weekly or monthly) to a central data-
base located at the Institute for Infectious Diseases, 
University of Bern, Switzerland. We restricted the 
dataset to hospitals that continuously reported bacte-
raemias during the whole study period (hospitals not 
reporting bacteraemias in 2013 were included if they 
reported bacteraemias in ≥ 4 calendar years from 2014 
to 2018). The information on hospital size and patient 
days was obtained using national data on hospital sta-
tistics [15].
Isolates included, microbiological and 
epidemiological data
Positive blood cultures were interpreted as bacteraemic 
episodes (i.e. bacteraemias). For this study, only bac-
teraemic episodes with E. faecalis and E. faecium were 
included. We excluded isolates of other enterococcal 
species (e.g. E. gallinarum or E. casseliflavus). Only the 
first isolate from an individual patient was considered 
for the current analysis.
The microbiological data included enterococcal species 
and antibiotic susceptibility patterns. Antimicrobial 
susceptibility was tested in the participating lab-
oratories according to the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) 
guidelines (https://eucast.org/) or the Clinical and 
Laboratory Standards Institute (CSLI) guidelines in a 
single laboratory (https://clsi.org/). Resistant isolates 
were defined as those that were resistant or interme-
diately susceptible to vancomycin, regardless of the 
underlying mechanism.
The epidemiological data available for each isolate 
allowed the stratification by sex and age, hospital 
type (community hospitals vs university hospitals), 
hospital size (< 200, 200–400, > 400 beds), hospi-
tal departments (intensive care unit (ICU) vs non-ICU 
departments) and geographical region (north-east 
vs. south-west). Clinical data (e.g. clinical diagnosis, 
source of infection, therapy, length of the hospital stay 
and outcomes) were not available.
Statistical analysis
Characteristics of patients with bacteraemia were 
described as count (per cent) or median (interquartile 
range (IQR)) for qualitative and quantitative variables, 
respectively, and were compared between groups 
using chi-squared or Wilcoxon test, as appropriate. 
The incidence of bacteraemias was calculated as the 
number of positive blood samples per 100,000 patient 
days. Incidence trends were assessed using Poisson 
regression with the offset being the log of patient days. 
The prevalence of vancomycin resistance among E. fae-
cium was calculated as the number of resistant strains 
over the total number of  E. faecium  isolates. Changes 
in the percentage were assessed using the Cochrane–
Armitage test and univariate logistic models.
We performed additional explanatory comparative 
analysis in order to identify variables associated with 
VRE.
Figure 1
Selection of enterococcal bacteraemic episodes for the 
nationwide surveillance study on vancomycin resistance 
among enterococcal bacteraemias, Switzerland, 2013–2018 
(n = 10,322 bacteraemic episodes)
All Enterococcus spp. bacteraemic episodes 01 
Jan 2013 to 31 Dec 2018 n = 10,322
Species other than E. faecium 
and E. faecalis n = 764
Duplicate isolates n = 3,037
Isolates from healthcare 
institutions without regular 
reporting n = 1,152
Bacteraemic episodes with E. faecium and E. 
faecalis n = 9,558
Bacteraemic episodes from 144 healthcare 
institutions n = 6,521
Included bacteraemic episodes from 81 
healthcare institutions n = 5,369
E. faecalis: Enterococcus faecalis; E. faecium: Enterococcus faecium.
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Confidential intervals (CI) were calculated and p val-
ues < 0.05 were considered to be statistically significant. 
We performed all analyses using R (Version 3.5.1). The 
current study followed the Strengthening the Reporting 
of Observational Studies in Epidemiology (STROBE) 
guidelines for observational studies [16].
Validation of database
We verified the accuracy of the ANRESIS database in 
reporting antibiotic resistance. We compared ANRESIS 
data with the results of a recently published nation-
wide survey on VRE epidemiology in Swiss hospitals 
performed in collaboration with the National Centre for 
Infection Control (Swissnoso) [12]. This survey included 
high-quality VRE data on samples obtained from 
patients with bacteraemic episodes, invasive infec-
tions and screening, which were collected by individual 
infection prevention specialists in 142 healthcare insti-
tutions in Switzerland. The numbers of VRE bacterae-
mias of individual hospitals, gathered from 1 January 
2015 to 31 March 2018 from 55 healthcare institutions, 
each represented both in the ANRESIS and in the sur-
vey database, were compared to test the accuracy of 
the ANRESIS database. This analysis was performed 
using Wilcoxon signed rank tests for paired data.
Ethical statement
As the analysis was performed on anonymised non-
genetic surveillance data, ethical consent was not 
required according to the Swiss law for research on 
humans (Article 33, Paragraph 2, Human Research Act).
Results
Isolates and hospitals included in the study
From 1 January 2013 to 31 December 2018, data on 
6,521 bacteraemic episodes with E. faecium and E. fae-
calis  from 144 Swiss healthcare institutions were sub-
mitted to ANRESIS. Sixty-three healthcare institutions 
were excluded because the collaboration with ANRESIS 
started after 2013 or the data reporting was incom-
plete. We included a total of 5,369 enterococcal bacte-
raemic episodes (Figure 1). The selected 81 healthcare 
institutions are displayed in  Figure 2  and represented 
ca 44% of all patient days in Switzerland during the 
whole study period. All five Swiss university hospitals 
were included in the analysis (a detailed comparison 
between included and excluded isolates is available in 
the Supplementary Table S1). 
Figure 2
Swiss healthcare institutions included in the nationwide surveillance study on vancomycin resistance among enterococcal 
bacteraemias, 2013–2018 (n = 81 institutions)
0 50
Kilometres
Annual patient days per hospital
North-east geographical region
South-west geographical region
 
10,000 
100,000
The disk sizes are proportional to the hospitals’ annual patient days. The background colours on the map represent geographical regions of 
Switzerland (green: north-east; blue: south-west).
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Epidemiological and microbiological 
characteristics of bacteraemia-derived isolates
Of the 5,369 samples obtained from bacteraemic 
patients, 2,173 (40.5%) were due to  E. faecium  and 
3,196 (59.5%) to  E. faecalis. Epidemiological charac-
teristics of patients with bacteraemia are summarised 
in  Table 1. Enterococcal bacteraemias occurred more 
frequently in men (n = 3,614; 67.3%) and the median 
age of all patients was 70 years (IQR: 60–80). The 
majority of the samples (2,760; 51.4%) were observed 
in hospitals with > 400 beds and 2,408 (44.9%) were 
from university hospitals. Almost 15 per cent of the 
patients (n = 780) were hospitalised in the ICU at the 
time of blood sampling.
Epidemiological characteristics differed between indi-
viduals with E. faecium and E. faecalis bacteraemias. E. 
faecalis  bacteraemias were more frequently observed 
in community hospitals compared to E. faecium bacte-
raemias (61.5% vs 45.8% respectively; p < 0.001) and in 
smaller hospitals (28.7% vs 17.1%; p < 0.001). Patients 
with  E. faecium  were more likely to be hospitalised in 
the ICU at time of bacteraemia diagnosis than patients 
with E. faecalis (19.3% vs 11.3%; p < 0.001). Antimicrobial 
resistance against vancomycin was generally low 
(n = 31; 0.6%) and was mainly observed among E. fae-
cium  isolates (1.4% vs 0% of E. faecalis bacteraemias; 
p < 0.001).
Trends in annual incidences of enterococcal 
bacteraemias between 2013 and 2018
The time trends for the annual incidences of enterococ-
cal bacteraemias are shown in Figure 3. The total num-
ber of episodes reported increased from 762 (2013) to 
922 (2018), which corresponded to an upward trend 
in incidence from 15.2 to 18.1 per 100,000 patient 
days (p < 0.01). We observed a 3.2% increase per year 
(95% CI: 1.6–4.8%; p < 0.001) that was explained by 
an increasing incidence of  E. faecalis  bacteraemias 
from 8.7 to 11.0 per 100,000 patient days (mean: 3.9% 
per year; 95% CI: 1.9–6.0%; p < 0.001). There was no 
significant increase in  E. faecium  incidence over the 
study period (from 6.5 to 7.1 per 100,000 patient days; 
p = 0.10).
In a post hoc subgroup analysis of E. faecalis, we found 
a marginally significant increase in non-ICU depart-
ments (from 86.7% in 2013 to 90.6% in 2018; p = 0.04, 
data not shown), whereas no significant trend was 
observed among other subgroups (i.e. age, sex, region, 
hospital size and hospital type).
Vancomycin-resistant isolates with time trend 
for Enterococcus faecium prevalence
A total of 30 vancomycin-resistant  E. faecium  isolates 
were identified over the study period. Their proportion 
increased from 0% (n = 0/326) in 2013 to 3.9% 
(n = 14/360) in 2018, corresponding to a 2.0% annual 
increase (95% CI: 1.5–2.9; p < 0.01) (Figure 4). Only one 
bacteraemic isolate of  E. faecalis, sampled in 2015, 
was resistant to vancomycin.
Table 1
Epidemiological characteristics of patients with Enterococcus faecium and E. faecalis bacteraemia, Switzerland, 2013–2018 
(n = 5,369 bacteraemias)
Characteristics
All bacteraemias 
 
(n = 5,369)
E. faecium 
 
(n = 2,173)
E. faecalis 
 
(n = 3,196)
p value
Age – year, median (IQR) 70 (60–80) 70 (55–75) 70 (60–80) < 0.001
Male sex – n (%) 3,614 (67.3) 1,388 (63.9) 2,226 (69.6) < 0.001
Department – n (%)
ICU 780 (14.5) 420 (19.3) 360 (11.3)
< 0.001
Non-ICU 4,589 (85.5) 1,753 (80.7) 2,836 (88.7)
Hospital type – n (%)
University hospital 2,408 (44.9) 1,177 (54.2) 1,231 (38.5)
< 0.001
Community hospital 2,961 (55.1) 996 (45.8) 1,965 (61.5)
Hospital size – n (%)
> 400 beds 2,760 (51.4) 1,276 (58.7) 1,484 (46.4)
< 0.001200–400 beds 1,321 (24.6) 525 (24.2) 796 (24.9)
< 200 beds 1,288 (24.0) 372 (17.1) 916 (28.7)
Geographical region – n (%)
South-west 2,066 (38.5) 814 (37.5) 1,252 (39.2)
0.22
North-east 3,303 (61.5) 1,359 (62.5) 1,944 (60.8)
Year – n (%)
2013 762 (14.2) 326 (15.0) 436 (13.6)
cf trend analysisa
2014 860 (16.0) 333 (15.3) 527 (16.5)
2015 948 (17.7) 402 (18.5) 546 (17.1)
2016 909 (16.9) 361 (16.6) 548 (17.1)
2017 968 (18.0) 391 (18.0) 577 (18.1)
2018 922 (17.2) 360 (16.6) 562 (17.6)
Vancomycin resistance – n (%) 31 (0.6) 30 (1.4) 1 (0) < 0.001
ICU: intensive care unit; IQR: interquartile range.
a For detailed analysis, see trend data.
5www.eurosurveillance.org
Additional analyses
During the first 3 years of the study period, we encoun-
tered only three blood cultures positive for vancomy-
cin-resistant  E. faecium, whereas between 2016 and 
2018 we observed 27. To identify epidemiological 
factors associated with the upward trend of VRE bac-
teraemias, we performed a post hoc analysis only for 
2016–2018, which revealed no significant factor asso-
ciated with the detection of vancomycin-resistant  E. 
faecium (Table 2).
Validation of the database used
Among the 55 healthcare institutions included in the 
accuracy analysis, 23 and 27 VRE bacteraemias were 
observed in the ANRESIS and in the survey data-
base, respectively. Regarding the accuracy analysis 
(Supplementary Figure S2), no significant difference 
in the reported number of VRE episodes of individual 
hospitals between the two databases was found in a 
Wilcoxon signed rank tests for paired data (p = 0.28). 
Two hospitals (3.6%) reported an identical number 
of positive samples and from 41 hospitals (74.6%) 
no bacteraemic episodes with VRE were detected in 
either database. Nine institutions (16.4%) showed a 
discrepancy of one sample, three (5.5%) a discrepancy 
of more than one sample. In summary, a high congru-
ency for bacteraemias was observed between the two 
databases.
Discussion
In this work, we report annual incidences of entero-
coccal and VRE bacteraemias in Switzerland and their 
evolution over a recent 6-year period, using data from 
ANRESIS. Including more than 80 healthcare institu-
tions and representing almost half of all patient days 
accrued in Switzerland per year, this database can be 
considered as representative for the entire country. 
As Switzerland does not participate in the EARS-Net, 
our data provide essential information on the epide-
miology of invasive enterococcal infections in Europe. 
Moreover, given the geographical location of the coun-
try at the crossroads of Europe, the findings are use-
ful for benchmarking purposes with other European 
countries.
From January 2013 to December 2018, a total of 5,369 
bacteraemic episodes with  E. faecalis  and  E. fae-
cium  were characterised.  E. faecalis  was the most 
prevalent  Enterococcus  species in all geographical 
regions of Switzerland. This was consistent with 
the results of the global antimicrobial surveillance 
programme SENTRY (1997–2016), which found a 
prevalence of enterococcal bloodstream infections 
reaching 10.7% of all bacteraemic isolates in North 
America and 8.1% in Europe, respectively [6].
In line with European trends [2,17], an increase in 
annual enterococcal bacteraemia incidence was found 
in Switzerland. This was mainly caused by an increase 
in E. faecalis bacteraemic episodes, particularly in non-
ICU hospital departments. The rate of E. faecalis causing 
bacteraemias in Europe, however, remained stable dur-
ing the last decade [17]. We do not have enough infor-
mation to explain the persisting upward trend for  E. 
faecalis in non-ICU departments in Switzerland. Further 
studies should focus on this setting in order to better 
delineate these findings.
Our study constitutes the first report on trends of 
VRE bacteraemia in Switzerland and an emerging 
proportion of vancomycin-resistant  E. faecium,  up 
to 3.9% in 2018, was observed. In our surveillance, 
we nevertheless found no significant increase in  E. 
Figure 3
Time trends for annual incidences of bacteraemias 
(number of bacteraemias per 100,000 patient days) due to 
Enterococcus faecalis and E. faecium, Switzerland, 2013–
2018 (n = 5,369 bacteraemias)
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The term ‘overall enterococci’ refers to the species included in this 
study.
Figure 4
Time trend for the proportion of vancomycin resistance 
among Enterococcus faecium bacteraemias, Switzerland, 
2013–2018 (n = 2,173 E. faecium bacteraemias)
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VRE: vancomycin resistance among E. faecium bacteraemias.
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faecium  incidence. In contrast to previously published 
data, which demonstrated the additional effect of 
antibiotic-resistant bacteria on the total burden of 
nosocomial bloodstream infections [18], the trends 
encountered here suggest that VRE  E. faecium  are 
replacing susceptible E. faecium isolates.
A global increase in the rates of vancomycin resistance 
among E. faecium was observed over the last few dec-
ades: according to surveillance data until 2016, this 
reached 21.0% in the United States and 9.9% in Europe 
[6]. Among European countries, however, a recent 
EARS-Net report described significant variability in 
vancomycin resistance rates for E. faecium (from 0% in 
Iceland, Luxemburg and Slovenia to 59.1% in Cyprus in 
2018) [8]. Concerning the VRE proportion in countries 
neighbouring Switzerland, France and Austria exhib-
ited low prevalences (0.6% and 2.1%, respectively) 
and decreasing trends until 2018 [8]. In Germany, 
in contrast, the VRE proportion among enterococcal 
bloodstream infection increased dramatically in the 
last years [19,20], with the proportion in 2018 being as 
high as 23.8% [8]. In Italy, an increasing VRE incidence 
was recently reported as well [8]. The exact reasons for 
the heterogeneous geographical VRE distribution pat-
tern are currently unknown, but are probably linked to 
infection control and antibiotic usage practices [21].
Since 2018, due to a large outbreak with an emer-
gent vancomycin-resistant clone (ST796) in the north-
east region of Switzerland [14], the awareness of this 
nosocomial pathogen has risen sharply. We describe 
a significant increase of the proportion of vancomy-
cin-resistant isolates among  E. faecium  bacteraemias, 
with no specific characteristic significantly associated 
to the higher prevalence of such isolates. Notably, no 
difference in proportions between the regions was 
observed. In light of these considerations, we hypoth-
esise that the spread of VRE in Switzerland appears to 
be homogeneously distributed throughout the country 
and started before the aforementioned outbreak.
Assuming that the observed trends are real, we won-
dered whether they could be associated with the hos-
pital setting. The included surveillance data, however, 
did not provide enough details to identify the role of 
healthcare-associated bacteraemias. A national sur-
vey in 2018 reported an increasing number of VRE out-
breaks in Swiss hospitals, thus suggesting nosocomial 
dissemination of VRE [12]. Moreover, a surveillance 
study conducted in Norway from 2006 to 2017, a coun-
try with low VRE prevalence, reported that over 85% of 
the VRE cases were associated with hospital outbreaks 
[22]. Also in Denmark, a cohort study revealed that the 
majority of enterococcal bacteraemias were hospital-
acquired [23].
Several factors may explain the observed trends in 
VRE bacteraemias. First, several Swiss institutions 
have not yet established an admission screening pol-
icy for detecting VRE carriers and reporting for VRE 
is not mandatory, which reduces the likelihood of an 
early detection of VRE clusters [24]. Due to the rela-
tively low risk (4%) of developing a bacteraemia for 
VRE-colonised patients [25], active surveillance is 
essential to thoroughly understand VRE epidemiology. 
Second, harmonised national infection prevention rec-
ommendations (e.g. contact precautions, single room, 
environmental decontamination) have not yet been 
developed and implemented throughout the country 
Table 2
Difference between epidemiological characteristics of vancomycin-susceptible and vancomycin-resistant Enterococcus 
faecium bacteraemias, Switzerland, 2016–2018 (n = 1,112 bacteraemias)
Characteristic
VSE bacteraemia 
 
(n = 1,085)
VRE bacteraemia 
 
(n = 27)
p value
Age – year, median (IQR) 70 (55–75) 65 (55–75) 0.60
Male sex – n (%) 685 (63.1) 15 (55.6) 0.55
Department – n (%)
ICU 210 (19.4) 7 (25.9)
0.55
Non-ICU 875 (80.6) 20 (74.1)
Hospital – n (%)
University hospital 573 (52.8) 17 (63.0)
0.40
Community hospital 512 (47.2) 10 (37.0)
Hospital size – n (%)
 > 400 beds 619 (57.1) 19 (70.4)
0.27200–400 beds 267 (24.6) 6 (22.2)
 < 200 beds 199 (18.3) 2 (7.4)
Geographic region – n (%)
South-west 420 (38.7) 9 (33.3)
0.71
North-east 665 (61.3) 18 (66.7)
Year – n (%)
2016 357 (32.9) 4 (14.8)
cf trend analysisa2017 382 (35.2) 9 (33.3)
2018 346 (31.9) 14 (51.9)
ICU: intensive care unit; IQR: interquartile range; VRE: vancomycin-resistant Enterococcus faecium; VSE: vancomycin-susceptible Enterococcus 
faecium.
a For detailed analysis, see trend data.
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[26]. Third, the consumption of cephalosporins and 
vancomycin, both important risk factors for VRE acqui-
sition [27,28], increased over the last decade in Swiss 
hospitals [29]. Fourth, a national survey conducted in 
2018 highlighted a substantial heterogeneity regarding 
the VRE outbreak containment strategies adopted by 
the different institutions [12]. To cope with this emer-
gent situation, a national VRE task force was created 
in 2018 in order to improve surveillance and facilitate 
the early detection of VRE outbreaks, to harmonise 
the communication between hospitals, and to prepare 
national guidelines with specific prevention measures 
[30]. Moreover, a national antimicrobial stewardship 
programme to decrease antibiotic consumption were 
recently introduced [26].
There are several limitations to the present study. 
First, we extrapolated incidence based on the epide-
miology of 44% of all Swiss healthcare institutes and, 
consequently, the generalisability of our findings may 
be somewhat limited. Nevertheless, in order to bet-
ter describe our cohort of hospitals, we reported dif-
ferences between included and excluded hospitals in 
a subgroup analysis. Second, we cannot exclude the 
possibility of multiple inclusions of follow-up species 
from one individual after transfer to a region served 
by another laboratory. Third, similarly to other resist-
ance surveillance databases, we did not have access 
to clinical data. For example, we were unable to dis-
tinguish between clinical infection and contamination. 
However, Enterococcus spp. is not a typical contaminant 
in blood cultures and therefore more likely to be the 
cause of bacteraemia if recovered [31,32]. Fourth, no 
information on molecular resistance mechanisms was 
available. Moreover, the clonality between enterococ-
cal strains was not assessed and, therefore, we were 
unable to confirm or rule out regional or inter-regional 
VRE spread of specific clones. Finally, due to the low 
incidence of VRE bacteraemias, we did not include 
cluster effects for the different healthcare institutions 
in the statistical analysis and the results of the sub-
group analysis may have been underpowered.
In conclusion, we detected an increasing proportion 
of bacteraemias due to vancomycin-resistant  E. fae-
cium  from 2013 to 2018 in Switzerland. In order to 
reduce the spread of VRE in Switzerland, both detection 
strategies and infection prevention and containment 
measures should be further developed and uniformly 
implemented.
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